Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 159,588 275,693 319,053 656,089
Total Sell Value $13,270,852 $23,760,160 $27,661,182 $61,420,002
Total People Sold 5 6 7 7
Total Sell Transactions 10 21 27 56
End Date 2024-03-10 2023-12-08 2023-06-09 2022-06-09

   
Records found: 1313
  Page 14 of 53  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-02-18 4 OE $26.49 $185,430 D/D 7,000 302,552     -
   Ho Maykin Director   –       •      –    2021-02-17 4 A $0.00 $0 D/D 2,350 2,350     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-02-17 4 AS $84.54 $676,320 D/D (8,000) 295,552     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-02-17 4 OE $26.49 $211,920 D/D 8,000 303,552     -
   Lawlis V Bryan Director   –       •      –    2021-02-16 4 AS $87.41 $655,575 D/D (7,500) 18,850     -
   Lawlis V Bryan Director   –       •      –    2021-02-16 4 OE $26.49 $198,675 D/D 7,500 26,350     -
   Mueller Brian EVP, Chief Financial Officer   •       –      –    2021-02-03 4 D $82.82 $88,700 D/D (1,071) 28,673     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-01-29 4 AS $82.67 $688,972 D/D (8,334) 295,552     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-01-29 4 OE $26.49 $220,768 D/D 8,334 303,886     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-01-28 4 AS $82.91 $690,889 D/D (8,333) 295,552     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-01-28 4 OE $26.49 $220,741 D/D 8,333 303,885     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-01-27 4 AS $85.49 $712,388 D/D (8,333) 295,552     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-01-27 4 OE $26.49 $220,741 D/D 8,333 303,885     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2020-12-29 4 AS $88.18 $132,270 D/D (1,500) 295,552     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2020-12-28 4 AS $88.77 $133,155 D/D (1,500) 297,052     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2020-10-14 4 AS $79.91 $169,489 D/D (2,121) 61,281     -
   Heron Elaine J Director   –       •      –    2020-10-07 4 OE $26.49 $397,350 D/D 15,000 66,968     -
   Pyott David E I Director   –       •      –    2020-08-31 4 B $78.22 $1,001,715 D/D 12,800 30,740 2.39     -
   Grey Michael G Director   –       •      –    2020-08-03 4 AS $120.35 $300,875 D/D (2,500) 42,840     -
   Grey Michael G Director   –       •      –    2020-08-03 4 OE $26.49 $66,225 D/D 2,500 45,340     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2020-07-20 4 AS $130.00 $16,430,570 D/D (126,389) 102,995     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2020-07-20 4 OE $63.10 $8,337,656 D/D 126,389 229,384     -
   Acosta Andrea GVP, Chief Accouning Officer   •       –      –    2020-07-17 4 D $128.21 $36,540 D/D (285) 14,674     -
   Acosta Andrea GVP, Chief Accounting OfficerO   •       –      –    2020-07-13 3 IO $0.00 $0 D/D 0 14,959     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2020-07-13 4 AS $130.00 $2,991,430 D/D (23,011) 102,995     -
  1313 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 14 of 53
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us